<0> INJEX Pharma AG and American Healthcare Products Inc. signed an exclusive distributor agreement to market needle-free syringe INJEX 30 in the West Coast States of USA </0>
<0> INJEX Pharma AGAndy RöschCEO INJEX Pharma AGTel.: 0049-30-53096768orSylwin GrinmanManaging Director INJEX Pharma USATel.: +1 786 512 196 3 </0>
American Healthcare Products Inc., headquartered in California, has been appointed as the exclusive distributor for USA West Coast states to market INJEX 30 in Washington State, California, Arizona, Nevada and Oregon. The agreement, includes a fixed minimum volume of 20,000 INJEX systems in the first year, was signed and the first delivery of products will start soon in August.
'We are excited about the partnership with INJEX Pharma AG. With FDA 510K approval for INJEX 30, we are very much convinced about the market opportunities in the dental, diabetes and medical markets. INJEX is the painless injection system and a safe alternative to the traditional needle syringe and a solution for needle phobics. But above all INJEX is an expression of the American way of life - basic rights of free choice for patients - and INJEX - the needle-free injection system is the better choice,' stated American Healthcare Products Inc. Managing Director Richard Lim.
In October, American Healthcare Products Inc. will present and highlight the INJEX 30 system and the needle-free treatments at the Annual Show of the American Dental Association (ADA) to the American dentists.
'We are focused on our network opportunities and immediate market approach. It's Time to market - we have the sales and marketing strategy in the exclusive states prepared, the logistics built up and our long term partners and customers integrated,' added Mr. Richard Lim.
'Together with American Healthcare Products Inc., we have a strong sales and marketing partner, which has been established in the market, experienced and has a first class network of institutions, associations and clinics. This is fundamental for the sales opportunities and we are looking forward to a successful market entry with our new partner in the US market,' remarks Mr. Andy Rösch, CEO of INJEX Pharma AG.